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Cutaneous vasculitis can be classiﬁed as primary or idiopathic; or secondary, when it presents as a manifestation of connective
tissue diseases, infections, drug reactions or malignancies. Although most of the idiopathic cases are self-limited and responsive
to supportive measures and nonsteroidal anti-inﬂammatory drugs, potent immunosuppressants are sometimes required for the
management of the refractory situations. Here we describe a case of a 32-year-old Caucasian female patient with history of
idiopathic cutaneous deep vasculitis unresponsive to methotrexate, dapsone, and cyclophosphamide who was eﬀectively treated
with inﬂiximab.
1.Introduction
Cutaneous vasculitis, a disease with an annual incidence rate
ranging from 39.6 to 59.8 per million [1], can be classiﬁed
as primary or idiopathic; or secondary, when it presents
as a manifestation of connective tissue diseases, infections,
drug reactions or malignancies [2]. Although most of the
idiopathic cases are self-limited and responsive to supportive
measures (limb elevation, warming, avoid standing) and
nonsteroidal anti-inﬂammatory drugs, potent immunosup-
pressants are sometimes required for the management of the
refractory situations [3].
We herein describe a case of a 32-year-old Cauca-
sian female patient with history of idiopathic cutaneous
deep vasculitis unresponsive to methotrexate, dapsone, and
cyclophosphamide, who was eﬀectively treated with inﬂix-
imab.
2.CaseReport
The patient felt well until September 2005, when palpable
painful nodules and multiple ulcerated lesions developed
in both legs and ankles. There was no history of arthritis,
rashes, photosensitivity, other skin lesions, mouth ulcers,
gastrointestinal, or urogenital symptoms. Antinuclear anti-
body (ANA), rheumatoid factor (RF), anti-neutrophil cyto-
plasmatic antibodies (ANCA), anti-RO, anti-LA, anti-HIV,
HBsAg, HCV, antistreptolysin O (ASO), and cryoglobulins
tested negative; complete blood count and a serum thyroid-
stimulating hormone (TSH) determination were normal, as
wereachestX-ray.Erythrocytesedimentationrate(ESR)and
C-reactive protein (CRP) were markedly elevated (90mmHg
on the ﬁrst hour and 45mg/dL—normal: 0–6mg/dL; resp.),
and there was a polyclonal gammopathy on a serum protein
electrophoresis test. Examination of a skin smear sample
to identify Mycobacterium leprae w a sn e g a t i v e .Ac u t a n e o u s
biopsy revealed ﬁbrinoid degeneration of the perivascular
and vessels walls collagen, as well as mononuclear and neu-
trophilic inﬁltrates extending to the deeper dermis and the
presence of leukocytoclasia, corroborating the diagnosis of
cutaneous deep vasculitis. The patient was given 60mg/day
of prednisone (approximately 1mg/kg), with merely partial
resolution of the signs and symptoms, even after 2 months
of appropriate usage (Figure 1). As a steroid-sparing drug,
methotrexate was given in a dosage up to 25mg/week,
unsuccessfully. Five monthly pulses of cyclophosphamide
(0.75g/m2/body surface) and dapsone 200mg/day were also
ineﬀective in reducing the oral prednisone dosage, and2 International Journal of Vascular Medicine
Figure 1: Vasculitic leg ulcer, in spite of the usage of high-dose
prednisone (1mg/kg/day).
Figure 2: By the fourth inﬂiximab infusion, the ulcers healed
completely and allowed steroids withdrawal.
when the reduction was attempted, the vasculitis signs and
symptoms recurred promptly. In August 2007, taking into
consideration these therapeutic failures, the patient was
started on infusions of 3mg/kg inﬂiximab on days 0, 15,
and 45 and then every 8 weeks. As early as by the fourth
infusion,prednisonedosagehadalreadybeentaperedtozero
and no vasculitis recurrence was observed (Figure 2). As of
January 2009, no recurrences have occurred and no adverse
drug eﬀects were registered.
3. Discussion
About 40% of all cases of cutaneous vasculitis are idiopathic
and, currently, no guidelines for its treatment are available.
Most of the episodes are self-limiting, lasting only a few days
or weeks, but in about 20% of cases, a chronic, unremitting
course, takes place, when immunosuppressants (azathio-
prine, methotrexate, cyclophosphamide, cyclosporine, or
mycophenolate mofetil) must be required [2].
Inﬂiximab, a chimeric anti-TNF-α antibody, has been
shown to be eﬀective in a variety of inﬂammatory and
autoimmune diseases, as rheumatoid arthritis, ankylosing
spondylitis, and Crohn’s disease [4]. Higher serum levels
of the proinﬂammatory cytokines TNF-α,I L - 1 β has already
been observed in small vessels cutaneous vasculitis patients
when compared to healthy subjects [5], suggesting a possible
role for these molecules in the pathogenesis of the disease.
Reports published by Mang et al. [6] and Uthman et al. [7]
also support the beneﬁt of inﬂiximab in cases of diﬃcult-to-
treat deep cutaneous vasculitis, even though in none of the
cases reported by those authors cyclophosphamide was tried
priortotheusageofbiologicaltherapy.Interestingly,McCain
et al. [8] described a case of cutaneous vasculitis related
to previous inﬂiximab infusions, probably due to antidrug
antibodies formation. Although inﬂiximab is a drug that has
been related to serious side eﬀects, these can be properly
monitored, identiﬁed, and managed, and its rapid onset of
action certainly favors its use in refractory idiopathic deep
cutaneous vasculitis.
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